stockrow
Saturday 7 November 2026
Export ENLV’s income statement to Excel — free account
Enlivex Ltd.
ENLV Healthcare Biotechnology
- EPS
- +5,349.9%
- Free cash flow
- +35.9%
Quarter to June 2026, against a year earlier
1.27
0.00
0.00%
Follow ENLV
Alert me
Enlivex Ltd. (ENLV) P/E ratio
As of 6 November 2026, Enlivex Ltd. (ENLV) trades at a P/E ratio of 0.0×. Over the past ten years it has ranged from 0.0× (December 2025) to 0.0× (March 2026); the current reading is higher than 93% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
93
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EDVA Splash Beverage Group, Inc. compare | n/m |
| BRTX Biorestorative Therapies, Inc. compare | n/m |
| SILO Silo Pharma, Inc. compare | n/m |
| GNPX GENPREX compare | n/m |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| PPCB Propanc Biopharma Inc compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| SLXN Silexion Therapeutics Corp compare | n/m |
| ENLV Enlivex Ltd. | 0.0× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)